Is Ultragenyx Stock a Buy After GTX-102 Flop? Analysts Point to Commercial Pipeline
5 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
"Is Ultragenyx Stock a Buy After GTX-102 Flop? Analysts Point to Commercial Pipeline" is generating significant coverage in the Business category, with 5 articles from 5 distinct sources tracked by PULSE so far.
Outlets currently covering the story include MarketBeat, finance.yahoo.com, STAT and Fierce Biotech. PULSE measures a story's velocity from how quickly new articles appear and how many independent newsrooms join the coverage.
This brief was generated by PULSE's extractive engine from coverage metadata only. The latest headlines from every source are listed below; the velocity chart shows how the story is developing in real time.
Generated by PULSE's extractive engine from coverage metadata only — no AI-written claims. Updated 6h ago.
Quick answers
Why is "Is Ultragenyx Stock a Buy After GTX-102 Flop? Analysts Point to Commercial Pipel" trending?
Because 5 independent news sources published 5 articles about it in a short window — a coverage burst PULSE classifies as a trend.
How does PULSE measure this trend?
PULSE scores velocity from the rate of new articles weighted by source diversity, snapshotted hourly. The full method is public on our methodology page.
Is this trend still active?
The status badge on this page updates hourly: rising, peaking, cooling, or archived once coverage stops for 48 hours.
Coverage (12)
- Ultragenyx vows 'significant' cuts after experimental rare-disease drug flunks late-stage clinical trial The Business Journals · 7h ago
- Why Did RARE Stock Slump 46% After-Hours? Yahoo Finance · 7h ago
- Ultragenyx drug to treat Angelman syndrome, a rare disease, fails late-stage trial STAT · 7h ago
- Ultragenyx to weigh ‘significant’ cost cuts as Angelman drug fails key study BioPharma Dive · 7h ago
- Ultragenyx to slash costs after Angelman trial failure pharmaphorum · 7h ago
- Ultragenyx mulls fate of rare disease programme on Phase III flop Clinical Trials Arena · 7h ago
- Ultragenyx Pharmaceutical (NASDAQ:RARE) Rating Lowered to "Equal Weight" at Wells Fargo & Company MarketBeat · 7h ago
- Ultragenyx Shares Fall After Phase 3 Aspire Study Misses Primary Endpoint finance.yahoo.com · 7h ago
- We’re reading about an Ultragenyx failure, RevMed for lung cancer, and more STAT · 7h ago
- Ultragenyx fails phase 3 Angelman test, plots ‘significant expense reductions’ Fierce Biotech · 7h ago
- Is Ultragenyx Stock a Buy After GTX-102 Flop? Analysts Point to Commercial Pipeline Barron's · 7h ago
- Ultragenyx's ASO fails in Angelman syndrome, triggering sell-off FirstWord PHARMA · 9h ago
Topics
Related trends
1Password Users Flee Platform After $300,000 Donation. Should You Run, Too?
4 news sources are covering this Technology story right now — PULSE is tracking how fast it spreads.
Stock Market Today: Treasury Yields Retreat on Fed Official’s Rate Comments, Yen Jumps
2 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
‘Soul Train Awards’ Revived After Three-Year Pause, Set to Return This November on Both BET and CBS (EXCLUSIVE)
5 news sources are covering this Entertainment story right now — PULSE is tracking how fast it spreads.
'Push reset': After struggles at Florida, DJ Lagway has found a new home (and himself) at Baylor
4 news sources are covering this Sports story right now — PULSE is tracking how fast it spreads.
What’s Next for Gold Prices After the Latest Rebound?
5 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Yen Gains After BOJ Hawk Leaves Door Open for Outsized Hike
4 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.